Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Apr 16, 2024

Daniel Barvin, VP of Operations and Patient Advocacy at Coya Therapeutics discusses the challenges of treating ALS (Amyotrophic Lateral Sclerosis) and the company's approach to developing therapies for this heterogeneous disease.  Focusing on a combination modality, Coya is developing therapies effective for sporadic and genetic ALS, targeting regulatory T cells and reducing inflammation to slow disease progression. Daniel, who carries a genetic variant for ALS and FTD (Frontotemporal Dementia), emphasizes the need for resources and support for the next generation of pre-symptomatic genetic ALS patients.  

Daniel explains, "Coya is based upon the discovery of Dr. Stanley Appel of Houston Methodist, that all neurodegenerative diseases, we believe, also autoimmune and a few metabolic diseases, drive an inflammatory response. The death of a motor neuron or damage to a motor neuron is an alert to the body that it should send inflammation to fix that motor neuron or beta-amyloid plaque buildup. Unfortunately, inflammation cannot fix these issues and, therefore, decides to take out a damaged part of the body. The death of the motor neuron then spurs more inflammation, and the inflammation that rises in the body eventually damages what are called regulatory T cells, the most immunomodulating cells in the body. Once regulatory T cells are damaged, inflammation becomes a persistent condition and drives further degeneration and eventually death."  

"Coya is founded upon the idea that we can affect the number and efficacy of regulatory T cells. This was our first pathway to affecting change in ALS. We have now gone to a combination therapy, which will be a biologic made up of two FDA-approved drugs in our own formulation. We believe this combination can increase the efficacy and number of regulatory T cells and reduce inflammation. We believe this combination effect in such a heterogeneous disease will have more efficacy than just a single modality."

$COYA #CoyaTherapeutics #ALS #GeneticALS #PresymptomaticALS #PatientAdvocacy #RareDiseases

Download the transcript here